269
Participants
Start Date
November 13, 2008
Primary Completion Date
April 22, 2010
Study Completion Date
April 22, 2010
Lisdexamfetamine Dimesylate (LDX)
optimal dose of 30, 50 or 70 mg once daily
Bioscience Research, LLC, Mount Kisco
Youth and Family Research Program/WPIC ADHD Research Program, Pittsburgh
CRI Worldwide, Philadelphia
Neuroscience, Inc., Herndon
Dominion Clinical Research, Midlothian
Triangle Neuropsychiatry, PLLC, Durham
Northwest Behavioral Research Center, Marietta
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Sarkis Clinical Trials, Gainesville
Clinical Neuroscience Solutions, Inc., Orlando
Amedica Research Institute, Inc., Hialeah
Miami Research Associates, South Miami
Janus Center for Psychiatric Research, West Palm Beach
Florida Clinical Research Center, LLC, Bradenton
CNS Healthcare, Memphis
Four Rivers Clinical Research, Inc., Paducah
Pedia Research LLC., Owensboro
University Hospitals of Cleveland Division of Child & Adolescent Psychiatry, Cleveland
Clinco Inc., Terre Haute
Bart Sangal, Troy
Innovis Health/Odyssey Research, Fargo
Capstone Clinical Research, Libertyville
Psychiatric Associates, Overland Park
Vince and Associates Clinical Research, Inc., Overland Park
CIENTIFICA, Inc. at Prairie View, Newton
Louisiana Research Associates, Inc., New Orleans
Clinical Study Centers, LLC, Little Rock
IPS Research Company, Oklahoma City
Bayou City Research, Ltd., Houston
Red Oak Psychiatry Associates P.A., Houston
ADHD Clinic of San Antonio, San Antonio
Future Search Trials, Austin
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas
Penninsula Research Associates, Inc., Rolling Hills Estates
Psychiatric Centers at San Diego (PCSD-Feighner Research Institute), San Diego
Valley Clinical Research, Inc., El Centro
Elite Clinical Trials, Inc., Wildomar
Summit Research Network, Portland
OCCI, INC (Oregon Center for Clinical Investigations, Inc.), Salem
OCCI, Eugene
Northwest Clinical Research Center, Bellevue
Children's Specialized Hospital, Toms River
Vermont Clinical Study Center, Burlington
Neuropsychiatric Associates, Woodstock
Lead Sponsor
Shire
INDUSTRY